J&J Expands Clinical Trial of COVID-19 Vaccine to Include Adolescents
Johnson & Johnson (J&J) has started dosing adolescents in an ongoing phase 2a trial evaluating its COVID-19 vaccine.
The randomized, placebo-controlled study, launched in September, is assessing the vaccine as both a single-dose and two-dose regimen. The trial, which initially enrolled healthy adults ages 18 to 55 years old in addition to adults 65 years and older, will now include teenagers ages 12 to 17 years.
The study is currently enrolling participants in the UK and Spain, with enrollment expected to begin soon in the U.S., Canada and the Netherlands, followed by Brazil and Argentina.